dpp 4 inhibitor glp 1 agonist DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits Role of DPP-4 Inhibitors in

These medications work by increasing feelings of fullness by slowing the rate at which the stomach empties, which can help reduce the urge to overeat

The present study aims to investigate comparative dementia risk with initiators of GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors in people with type 2 diabetes aged 60 years, using real-world observational data from primary care practice records in the UK

Collectively, these advancements are reshaping treatment protocols and boosting the role of GLP-1 therapies in chronic disease management

It may be delivered through patches, gels, sprays, or oral formulations

Proactive blood pressure management is essential for patients initiating or continuing GLP-1 therapy, particularly those with risk factors for hypotension

These early indicators validate the compounds dual mechanism, which leverages GLP-1 for appetite suppression and glucagon to accelerate energy expenditure and fat reduction in the liver, positioning DA-1726 as a potent contender in the metabolic therapeutic landscape